BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1622637)

  • 1. Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
    Pfeiffer P; Cold S; Rose C
    Acta Oncol; 1992; 31(2):219-24. PubMed ID: 1622637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
    Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
    Gregory RK; Powles TJ; Chang JC; Ashley S
    Eur J Cancer; 1997 Nov; 33(13):2194-7. PubMed ID: 9470805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
    Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
    Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
    Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
    J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
    Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
    Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy in breast cancer.
    Dorr A
    Curr Opin Oncol; 1990 Dec; 2(6):1049-52. PubMed ID: 2099836
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
    Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
    Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Vogel CL; Raney M; Carpenter J
    Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapy of metastasizing breast cancer].
    Wascher H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):590-4. PubMed ID: 3841627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
    Venturini M; Bruzzi P; Del Mastro L; Garrone O; Bertelli G; Guelfi M; Pastorino S; Rosso R; Sertoli MR
    J Clin Oncol; 1996 Mar; 14(3):764-73. PubMed ID: 8622022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel combination therapy in the treatment of metastatic breast cancer.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):29-39. PubMed ID: 8941408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
    Carter SK
    Postgrad Med; 1985 Jan; 77(1):75-7, 80-3. PubMed ID: 3880891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.